BBH is an exchange-traded fund — it holds a basket of underlying assets rather than being a single operating company.
Company fundamentals like P/E, revenue, EPS and profit margins don't apply to a fund — its value comes from the assets it holds, not its own earnings. Use the price chart, options and model forecast below for fund-level analysis.
An institutional-grade, numbers-driven thesis on BBH — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates VanEck Biotech ETF (BBH) 55/100 with a 12-month base-case forecast of $245.97 — +16.4% versus the current price of $211.34. VanEck Biotech ETF trades at $211.34 in the Financial Services sector, with a market capitalisation of $366.9M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for BBH is $245.97, implying +16.4% versus the current price. The model's 12-month scenario range runs from $229.17 (bear) to $273.13 (bull), with a base case of $245.97.
BBH currently carries a TradersQuant composite score of 55/100, which we read as a neutral-to-watch signal. Our 12-month price target of $245.97 implies +16.4% from $211.34. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for BBH is $245.97, about +16.4% versus the latest price of $211.34.
TradersQuant's 12-month model forecast for BBH is a base case of $245.97, ranging from $229.17 (bear) to $273.13 (bull), an expected return of +16.4%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for BBH over the next 12 months is $245.97 in the base case (bear $229.17, bull $273.13), versus today's price of $211.34. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for BBH — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates BBH's fair value at $269.45, implying +27.5% of expected upside versus the current price.
VanEck Biotech ETF does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
